On Friday, Cliffs Natural Resources Inc (NYSE:CLF)’s shares declined -6.76% to $2.69.
First Point Minerals Corp. provide a corporate update on the status of its 40%-owned Decar nickel project (“Decar” or the “Project”), located in central British Columbia.
Following the option agreement reached in November 2009 between First Point and Cliffs Natural Resources Exploration Canada Inc., an associate of Cliffs Natural Resources Inc. (CLF) (“Cliffs”), effective recently the structure of Project ownership has converted to a contractual joint venture, on pre-agreed terms, with initial ownership interests fixed at the current levels of 60% for Cliffs and 40% for First Point.
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore and metallurgical coal. It operates five iron ore mines that produces iron ore pellets in Michigan and Minnesota; Koolyanobbing complex situated in northeast of the town of Southern Cross, which produces lump and fines iron ore; and two metallurgical coal mines located in Alabama and West Virginia.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s shares dropped -6.33% to $12.20.
ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, recently declared that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response.
The FDA’s Office of Orphan Products grants orphan drug status to support development of medicines for underserved patient populations or rare disorders affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides eligibility for a seven-year period of market exclusivity in the United States after product approval, an accelerated review process, accelerated approval where appropriate, grant funding, tax benefits and an exemption from user fees.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnershipwith Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
At the end of Friday’s trade, Pepco Holdings, Inc. (NYSE:POM)‘s shares dipped -0.07% to $26.86.
Pepco Holdings, Inc. (POM) stated second quarter and six months ended June 30, 2015 merged earnings as follows:
Pepco Holdings’ GAAP net income for each of the three month periods ended June 30, 2015 and 2014, was $53 million, or 21 cents per share. Not taking into account items that we believe are not representative of ongoing business operations, adjusted earnings for the second quarter of 2015 would have been $57 million, or 23 cents per share as contrast to $71 million, or 28 cents per share for the same period in 2014.
The primary drivers of the decrease in adjusted net income (Non-GAAP) in the second quarter of 2015, as contrast to the same quarter in 2014, were higher operation and maintenance expense (primarily due to the implementation of a new customer information system and raised distribution system maintenance) and higher depreciation expense from raised plant investment. Higher electric distribution revenue and default supply margins partially offset the decrease for the second quarter.
Pepco Holdings, Inc., through its auxiliaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. In addition, the company designs, constructs, and operates energy projects and distributed generation equipment, counting combined heat and power plants principally for federal, state, and local government customers.
Castlight Health Inc (NYSE:CSLT), ended its Friday’s trading session with -6.05% loss, and closed at $6.06.
Castlight Health, Inc. (CSLT), the leader in enterprise healthcare administration (EHM), recently declared that the company will present at the two following conferences.
Chief Financial Officer John Doyle will present at the Pacific Crest Global Technology Leadership Forum in Vail, Colorado. The presentation is planned for Monday, August 10, 2015 at 2:30 p.m. Mountain Time and will be webcast live.
Castlight Health, Inc. provides cloud-based software in the United States. Its software enables enterprises to understand and manage health care spending. It offers Enterprise Healthcare Cloud that transforms external and internal complex data into transparent and useful information.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
